Anacetrapib is a cholesterol ester transfer protein (CETP) inhibitor that exhibits anti-atherosclerotic activity. In vivo, anacetrapib inhibits the development of atherosclerosis and decreases levels of VLDL and PCSK9. In a clinical setting, this compound decreases levels of LDL and ApoB. Additionally, anacetrapib may increase levels of HDL and ApoA1.
| Purity | ≥98% |
|---|---|
| Formula | C30H25F10NO3 |
| Formula Wt. | 637.52 |
| Synonym | MK-0859 |
| Appearance | White powder |
| Store Temp | -20°C |
|---|
| Info Sheet | A5301 Info Sheet PDF |
|---|
van der Tuin SJ, Kühnast S, Berbée JF, et al. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. J Lipid Res. 2015 Nov;56(11):2085-93. PMID: 26342106.
Millar JS, Reyes-Soffer G, Jumes P, et al. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest. 2015 Jun;125(6):2510-22. PMID: 25961461.
Äijänen T, Koivuniemi A, Javanainen M, et al. How anacetrapib inhibits the activity of the cholesteryl ester transfer protein? Perspective through atomistic simulations. PLoS Comput Biol. 2014 Nov 20;10(11):e1003987. PMID: 25412509.
Hooper AJ, Burnett JR. Anacetrapib, a cholesteryl ester transfer protein inhibitor. Expert Opin Investig Drugs. 2012 Jan;21(1):103-9. PMID: 22191425.
